Synergy between BRAF inhibition, tumor-localized T cells and a persistent vaccine

BRAF 抑制、肿瘤定位 T 细胞和持久性疫苗之间的协同作用

基本信息

  • 批准号:
    8635992
  • 负责人:
  • 金额:
    $ 7.52万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-04-01 至 2015-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Abstract: A long-standing goal for melanoma immune therapy is the induction of tumor-specific T cells that effectively delay tumor progression and prolong overall patient survival. Several vaccination strategies have been attempted without success, despite often stimulating large numbers of tumor-specific T cells. Some of this failure is likely due to the active immune suppression mechanisms that operate within tumors. Moreover, it has become apparent that T cell trafficking and migration into tumors will be heavily influenced by the conditions in which those T cells were stimulated. Thus, the ideal cancer vaccine would overcome the immune suppressive environment of the tumor and produce cells that readily migrate into the primary tumor and metastases, wherever they may be. We argue here that a persistent vaccine vector, based on a spread- defective version of the herpes virus cytomegalovirus (CMV), may overcome some of these obstacles. Specifically, persistent CMV-based vectors will continuously boost the immune system outside of the tumor environment and produce T cells that are highly effective at migrating systemically. Our previous work demonstrated that a safe, spread-defective variant of CMV could persist and stimulate large T cell responses. Our aim for this small grant application is to determine the potential for (or limitations of) such a vaccine strategy. To accomplish this, we will use a newly generated, highly relevant model of metastatic melanoma: mice in which expression of a mutant BRAF (BRAFV600E) is induced. BRAF is a serine/threonine kinase that is mutated in ~50% of human melanomas and the BRAFV600E mutation is present in ~80 to 90% of human BRAF-mutant melanomas. Thus, this model mimics human disease. Most excitingly, this model enables us to combine BRAF inhibition with vaccination. This is a great advantage important because BRAF inhibitors, such as the recently FDA approved Vemurafenib, will be widely used in the clinic and recent data suggest that Vemurafenib may synergize with immune therapies. Here we will test the efficacy of CMV-based vaccination in the presence or absence of Vemurafenib inhibition of BRAF, with specific focus on T cell infiltration of tumors and function within tumors.
描述(由申请人提供):摘要:黑色素瘤免疫治疗的一个长期目标是诱导肿瘤特异性T细胞,有效地延缓肿瘤进展并延长患者的总体生存期。已经尝试了几种疫苗接种策略,但没有成功,尽管经常刺激大量的肿瘤特异性T细胞。其中一些失败是 这可能是由于肿瘤内的主动免疫抑制机制。此外,已经变得明显的是,T细胞运输和迁移到肿瘤中将受到严重影响。 T细胞被刺激的条件。因此,理想的癌症疫苗将克服肿瘤的免疫抑制环境,并产生容易迁移到原发性肿瘤和转移瘤中的细胞,无论它们在哪里。我们在这里认为,一个持久的疫苗载体,基于传播缺陷版本的疱疹病毒巨细胞病毒(CMV),可能会克服这些障碍。具体而言,持续的CMV载体将持续增强肿瘤环境外的免疫系统,并产生在全身迁移方面非常有效的T细胞。我们以前的工作表明,一种安全的,传播缺陷的CMV变体可以持续存在并刺激大的T细胞反应。我们申请这项小额资助的目的是确定这种疫苗策略的潜力(或局限性)。为了实现这一目标,我们将使用新生成的高度相关的转移性黑色素瘤模型:诱导突变BRAF(BRAFV 600 E)表达的小鼠。BRAF是一种丝氨酸/苏氨酸激酶,在约50%的人黑色素瘤中突变,BRAFV 600 E突变存在于约80 - 90%的人BRAF突变型黑色素瘤中。因此,该模型模拟人类疾病。最令人兴奋的是,这个模型使我们能够将联合收割机BRAF抑制与疫苗接种结合起来。这是一个很大的优势,因为BRAF抑制剂,如最近FDA批准的Vemurafenib,将广泛用于临床,最近的数据表明,Vemurafenib可能与免疫疗法协同作用。在这里,我们将测试在存在或不存在Vemurafenib抑制BRAF的情况下基于CMV的疫苗接种的功效,特别关注肿瘤的T细胞浸润和肿瘤内的功能。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Christopher M Snyder其他文献

Christopher M Snyder的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Christopher M Snyder', 18)}}的其他基金

An animal model for cytomegalovirus-induced pathology in the developing retina
发育中视网膜中巨细胞病毒诱导病理学的动物模型
  • 批准号:
    10432947
  • 财政年份:
    2022
  • 资助金额:
    $ 7.52万
  • 项目类别:
An animal model for cytomegalovirus-induced pathology in the developing retina
发育中视网膜中巨细胞病毒诱导病理学的动物模型
  • 批准号:
    10559671
  • 财政年份:
    2022
  • 资助金额:
    $ 7.52万
  • 项目类别:
T cell control of MCMV and tissue-localized immune suppression
T 细胞对 MCMV 的控制和组织局部免疫抑制
  • 批准号:
    10579272
  • 财政年份:
    2020
  • 资助金额:
    $ 7.52万
  • 项目类别:
T cell control of MCMV and tissue-localized immune suppression
T 细胞对 MCMV 的控制和组织局部免疫抑制
  • 批准号:
    10348755
  • 财政年份:
    2020
  • 资助金额:
    $ 7.52万
  • 项目类别:
Selection of inflationary and tissue-resident T cells during MCMV infection
MCMV 感染期间膨胀和组织驻留 T 细胞的选择
  • 批准号:
    8986152
  • 财政年份:
    2014
  • 资助金额:
    $ 7.52万
  • 项目类别:
Selection of inflationary and tissue-resident T cells during MCMV infection
MCMV 感染期间膨胀和组织驻留 T 细胞的选择
  • 批准号:
    8651139
  • 财政年份:
    2014
  • 资助金额:
    $ 7.52万
  • 项目类别:
Selection of inflationary and tissue-resident T cells during MCMV infection
MCMV 感染期间膨胀和组织驻留 T 细胞的选择
  • 批准号:
    9198197
  • 财政年份:
    2014
  • 资助金额:
    $ 7.52万
  • 项目类别:
Selection of inflationary and tissue-resident T cells during MCMV infection
MCMV 感染期间膨胀和组织驻留 T 细胞的选择
  • 批准号:
    8786495
  • 财政年份:
    2014
  • 资助金额:
    $ 7.52万
  • 项目类别:
Selection of inflationary and tissue-resident T cells during MCMV infection
MCMV 感染期间膨胀和组织驻留 T 细胞的选择
  • 批准号:
    8690204
  • 财政年份:
    2013
  • 资助金额:
    $ 7.52万
  • 项目类别:
Synergy between BRAF inhibition, tumor-localized T cells and a persistent vaccine
BRAF 抑制、肿瘤定位 T 细胞和持久性疫苗之间的协同作用
  • 批准号:
    8486040
  • 财政年份:
    2013
  • 资助金额:
    $ 7.52万
  • 项目类别:

相似海外基金

RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 7.52万
  • 项目类别:
    Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 7.52万
  • 项目类别:
    Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.52万
  • 项目类别:
    Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.52万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.52万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 7.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 7.52万
  • 项目类别:
    Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
  • 批准号:
    2301846
  • 财政年份:
    2023
  • 资助金额:
    $ 7.52万
  • 项目类别:
    Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 7.52万
  • 项目类别:
    Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
  • 批准号:
    23K16076
  • 财政年份:
    2023
  • 资助金额:
    $ 7.52万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了